The Department of Health finds itself at the centre of a heated national debate. The controversy surrounds the recent R15.5bn AIDS drug tender. It has reignited a long-standing conflict between fiscal austerity and industrial growth. Should the state prioritise the lowest possible price, or should it pay a premium for local pharmaceutical manufacturing? The Tension Between Budget Cuts and Industrial…